TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 8B 16B 24B Q1 '16: 19.5B Q4 '16: 21.9B Q1 '17: 22.7B Q2 '17: 23.4B Q3 '17: 23.5B Q4 '17: 22.4B Q1 '18: 21.8B Q2 '18: 20.8B Q3 '18: 19.7B Q4 '18: 18.7B Q1 '19: 17.8B Q2 '19: 17.3B Q3 '19: 16.8B Q4 '19: 16.9B Q1 '20: 17.1B Q2 '20: 16.8B Q3 '20: 16.7B Q4 '20: 16.7B Q1 '21: 16.3B Q2 '21: 16.3B Q3 '21: 16.2B Q4 '21: 15.9B Q1 '22: 15.6B Q2 '22: 15.4B Q3 '22: 15.1B Q4 '22: 14.9B Q1 '23: 14.9B Q2 '23: 15B Q3 '23: 15.3B Q4 '23: 15.8B Q1 '24: 16B Q2 '24: 16.3B Q3 '24: 16.8B Q4 '24: 16.5B Q1 '25: 16.6B Q2 '25: 16.6B Q3 '25: 16.8B Q4 '25: 17.3B Q1 '26: 17.3B Q2 '26: 17.3B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 5B 10B 15B Q1 '16: 11.3B Q4 '16: 11.7B Q1 '17: 11.9B Q2 '17: 11.9B Q3 '17: 11.7B Q4 '17: 10.8B Q1 '18: 10.3B Q2 '18: 9.4B Q3 '18: 8.8B Q4 '18: 8.3B Q1 '19: 7.8B Q2 '19: 7.7B Q3 '19: 7.5B Q4 '19: 7.5B Q1 '20: 7.7B Q2 '20: 7.6B Q3 '20: 7.6B Q4 '20: 7.7B Q1 '21: 7.5B Q2 '21: 7.7B Q3 '21: 7.6B Q4 '21: 7.6B Q1 '22: 7.5B Q2 '22: 7.4B Q3 '22: 7.3B Q4 '22: 7B Q1 '23: 6.8B Q2 '23: 6.8B Q3 '23: 7B Q4 '23: 7.6B Q1 '24: 7.8B Q2 '24: 8.1B Q3 '24: 8.4B Q4 '24: 8.1B Q1 '25: 8.2B Q2 '25: 8.2B Q3 '25: 8.4B Q4 '25: 8.9B Q1 '26: 9B Q2 '26: 9.1B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Income TTM

-18B -12B -6B 0 6B 12B 18B Q3 '15: 3.4B Q4 '15: 3.4B Q1 '16: 3.8B Q2 '16: 3.5B Q3 '16: 3.2B Q4 '17: -17.5B Q1 '18: -16.9B Q2 '18: -11.1B Q3 '18: -11.5B Q4 '18: -1.6B Q1 '19: -3B Q2 '19: -3.7B Q3 '19: -3.8B Q4 '19: -443M Q1 '20: -386M Q2 '20: 431M Q3 '20: -3.8B Q4 '20: -3.6B Q1 '21: -3.3B Q2 '21: -2.9B Q3 '21: 2B Q4 '21: 1.7B Q1 '22: 570M Q2 '22: -961M Q3 '22: -1.2B Q4 '22: -2.2B Q1 '23: -1.5B Q2 '23: -1.2B Q3 '23: -1.3B Q4 '23: 433M Q1 '24: 228M Q2 '24: 877M Q3 '24: 482M Q4 '24: -303M Q1 '25: 434M Q2 '25: 894M Q3 '25: 1.8B Q4 '25: 2.2B Q1 '26: 2.3B Q2 '26: 1.6B Q3 '16 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-18B -12B -6B 0 6B 12B 18B Q3 '14: 2.7B Q4 '14: 3.1B Q1 '15: 2.8B Q2 '15: 2.5B Q3 '15: 1.8B Q4 '15: 1.6B Q1 '16: 1.8B Q2 '16: 1.5B Q3 '16: 1.8B Q4 '17: -16.3B Q1 '18: -15.8B Q2 '18: -10B Q3 '18: -10.8B Q4 '18: -2.1B Q1 '19: -3.4B Q2 '19: -3.9B Q3 '19: -4B Q4 '19: -998M Q1 '20: -824M Q2 '20: 5M Q3 '20: -4B Q4 '20: -4B Q1 '21: -4B Q2 '21: -3.9B Q3 '21: 726M Q4 '22: -2.4B Q1 '23: -1.7B Q2 '23: -2.3B Q3 '23: -2.3B Q4 '23: -559M Q1 '24: -478M Q2 '24: -452M Q3 '24: -958M Q4 '24: -1.6B Q1 '25: -1.3B Q2 '25: -158M Q3 '25: 712M Q4 '25: 1.4B Q1 '26: 1.6B Q2 '26: 706M Q3 '15 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 4B 8B 12B Q1 '16: 8.2B Q4 '16: 10.2B Q1 '17: 10.8B Q2 '17: 11.5B Q3 '17: 11.7B Q4 '17: 11.2B Q1 '18: 11.2B Q2 '18: 11B Q3 '18: 10.6B Q4 '18: 10B Q1 '19: 9.5B Q2 '19: 9.1B Q3 '19: 8.8B Q4 '19: 9.4B Q1 '20: 9.4B Q2 '20: 9.2B Q3 '20: 9B Q4 '20: 8.9B Q1 '21: 8.7B Q2 '21: 8.7B Q3 '21: 8.6B Q4 '21: 8.3B Q1 '22: 8.1B Q2 '22: 8.1B Q3 '22: 7.9B Q4 '22: 8B Q1 '23: 8.1B Q2 '23: 8.2B Q3 '23: 8.3B Q4 '23: 8.2B Q1 '24: 8.2B Q2 '24: 8.2B Q3 '24: 8.4B Q4 '24: 8.5B Q1 '25: 8.4B Q2 '25: 8.4B Q3 '25: 8.4B Q4 '25: 8.3B Q1 '26: 8.3B Q2 '26: 8.2B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

0 2B 4B 6B Q1 '16: 5.6B Q4 '16: 3.9B Q1 '17: 4B Q2 '17: 3.5B Q3 '17: 2.8B Q4 '17: 2.2B Q1 '18: 3.6B Q2 '18: 3.3B Q3 '18: 2.9B Q4 '18: 2.4B Q1 '19: 1.1B Q2 '19: 673M Q3 '19: 577M Q4 '19: 748M Q1 '20: 941M Q2 '20: 1.4B Q3 '20: 1.4B Q4 '20: 1.2B Q1 '21: 506M Q2 '21: 451M Q3 '21: 673M Q4 '21: 798M Q1 '22: 1.2B Q2 '22: 1.1B Q3 '22: 1.1B Q4 '22: 1.6B Q1 '23: 1.5B Q2 '23: 1.7B Q3 '23: 1.2B Q4 '23: 1.4B Q1 '24: 1.4B Q2 '24: 1.2B Q3 '24: 1.9B Q4 '24: 1.2B Q1 '25: 1.3B Q2 '25: 1.4B Q3 '25: 1.1B Q4 '25: 1.6B Q1 '26: 1.7B Q2 '26: 1.9B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-2B 0 2B 4B 6B Q1 '16: 4.8B Q4 '16: 3B Q1 '17: 3.1B Q2 '17: 2.5B Q3 '17: 1.9B Q4 '17: 1.4B Q1 '18: 2.8B Q2 '18: 2.5B Q3 '18: 2.2B Q4 '18: 1.8B Q1 '19: 449M Q2 '19: 84M Q3 '19: -42M Q4 '19: 223M Q1 '20: 413M Q2 '20: 894M Q3 '20: 902M Q4 '20: 638M Q1 '21: -94M Q2 '21: -131M Q3 '21: 88M Q4 '21: 236M Q1 '22: 585M Q2 '22: 476M Q3 '22: 514M Q4 '22: 1B Q1 '23: 964M Q2 '23: 1.2B Q3 '23: 608M Q4 '23: 842M Q1 '24: 878M Q2 '24: 679M Q3 '24: 1.4B Q4 '24: 749M Q1 '25: 765M Q2 '25: 890M Q3 '25: 578M Q4 '25: 1.1B Q1 '26: 1.2B Q2 '26: 1.3B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 500M 1B 1.5B Q2 '13: 849M Q3 '13: 846M Q1 '14: 852M Q2 '14: 857M Q3 '14: 861M Q1 '15: 859M Q2 '15: 859M Q3 '15: 862M Q1 '16: 920M Q2 '16: 920M Q3 '16: 984M Q1 '17: 1B Q2 '17: 1B Q3 '17: 1B Q1 '18: 1B Q2 '18: 1B Q3 '18: 1B Q1 '19: 1.1B Q2 '19: 1.1B Q3 '19: 1.1B Q1 '20: 1.1B Q2 '20: 1.1B Q3 '20: 1.1B Q1 '21: 1.1B Q2 '21: 1.1B Q3 '21: 1.1B Q1 '22: 1.1B Q2 '22: 1.1B Q3 '22: 1.1B Q1 '23: 1.1B Q2 '23: 1.1B Q3 '23: 1.1B Q1 '24: 1.1B Q2 '24: 1.1B Q3 '24: 1.1B Q1 '25: 1.2B Q2 '25: 1.2B Q3 '25: 1.2B Q1 '26: 1.2B Q2 '26: 1.2B Q3 '14 Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q1 '15: 3.21 Q2 '15: 2.97 Q3 '15: 2.07 Q4 '15: 1.83 Q1 '16: 1.93 Q4 '16: 0.07 Q1 '17: 0.10 Q2 '17: -6.04 Q3 '17: -5.87 Q4 '17: -16.26 Q1 '18: -15.80 Q2 '18: -10.10 Q3 '18: -10.89 Q4 '18: -2.33 Q1 '19: -3.46 Q2 '19: -3.85 Q3 '19: -3.87 Q4 '19: -0.92 Q1 '20: -0.76 Q2 '20: 0.00 Q3 '20: -3.68 Q4 '20: -3.64 Q1 '21: -3.63 Q2 '21: -3.57 Q3 '21: 0.66 Q4 '22: -2.19 Q1 '23: -1.53 Q2 '23: -2.10 Q3 '23: -2.09 Q4 '23: -0.50 Q1 '24: -0.42 Q2 '24: -0.39 Q3 '24: -0.84 Q4 '24: -1.45 Q1 '25: -1.15 Q2 '25: -0.16 Q3 '25: 0.60 Q4 '25: 1.20 Q1 '26: 1.33 Q2 '26: 0.60 Q1 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.